Antibody-recruiting molecules: An emerging paradigm for engaging immune function in treating human disease

ACS Chemical Biology

Volumn 7, Issue 7, 2012, Pages 1139-1151

  McEnaney, Patrick J ^a   Parker, Christopher G ^a   Zhang, Andrew X ^a   Spiegel, David A ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ANTIBODY; ANTIBODY RECRUITING MOLECULE; PALIVIZUMAB; UNCLASSIFIED DRUG; VANCOMYCIN;

BACTERIAL INFECTION; DISEASES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOBIOLOGY; MOLECULAR RECOGNITION; NEOPLASM; NONHUMAN; ORGANIC CHEMISTRY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; VIRUS INFECTION;

ANIMALS; ANTIBODIES; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; TREATMENT OUTCOME;

EID: 84864133677     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb300119g     Document Type: Review

References (177)

1. Riedel, S. (2005) Edward Jenner and the history of smallpox and vaccination Proc. (Baylor Univ. Med. Cent.) 18, 21-25
2. Casadevall, A., Dadachova, E., and Pirofski, L. A. (2004) Passive antibody therapy for infectious diseases Nat. Rev. Microbiol. 2, 695-703
3. Elbakri, A., Nelson, P. N., and Abu Odeh, R. O. (2010) The state of antibody therapy Hum. Immunol. 71, 1243-1250
4. Ledford, H. (2010) 'Biosimilar' drugs poised to penetrate market Nature 468, 18-19
5. Aggarwal, S. (2009) Whatβs fueling the biotech engine-2008 Nat. Biotechnol. 27, 987-993
6. Reichert, J. M. (2011) Antibody-based therapeutics to watch in 2011 MAbs 3, 76-99
7. (2012) FDA Approved Drug Products, In http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm, U.S. Food and Drug Administration.
8. Weiner, L. M., Surana, R., and Wang, S. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy Nat. Rev. Immunol. 10, 317-327
9. Forecasting, B. R. M. (2011) Antibody Drugs: Technologies and Global Markets, BIO016H ed., BCC Research Market Forecasting.
10. Visintin, M., Melchionna, T., Cannistraci, I., and Cattaneo, A. (2008) In vivo selection of intrabodies specifically targeting protein-protein interactions: A general platform for an "undruggable" class of disease targets J. Biotechnol. 135, 1-15
11. Sunada, H., Magun, B. E., Mendelsohn, J., and MacLeod, C. L. (1986) Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation Proc. Natl. Acad. Sci. U.S.A. 83, 3825-3829
12. Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., and Ferguson, K. M. (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7, 301-311
13. Capala, J. and Bouchelouche, K. (2010) Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy Curr. Opin. Oncol. 22, 559-566
14. Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., Law, C.-L., Doronina, S. O., Siegall, C. B., Senter, P. D., and Wahl, A. F. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 102, 1458-1465
15. Alley, S. C., Okeley, N. M., and Senter, P. D. (2010) Antibody-drug conjugates: Targeted drug delivery for cancer Curr. Opin. Chem. Biol. 14, 529-537
16. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., and Ravetch, J. V. (1998) Fc receptors are required in passive and active immunity to melanoma Proc. Natl. Acad. Sci. U.S.A. 95, 652-656
17. Clynes, R. A., Towers, T. L., Presta, L. G., and Ravetch, J. V. (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat. Med. 6, 443-446
18. Sampson, J. H., Crotty, L. E., Lee, S., Archer, G. E., Ashley, D. M., Wikstrand, C. J., Hale, L. P., Small, C., Dranoff, G., Friedman, A. H., Friedman, H. S., and Bigner, D. D. (2000) Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors Proc. Natl. Acad. Sci. U.S.A. 97, 7503-7508
19. Murphy, K. P., Travers, P., Walport, M., and Janeway, C. (2008) Janewayβs Immunobiology, Garland Science, New York
20. Nimmerjahn, F. and Ravetch, J. V. (2008) Fcγ receptors as regulators of immune responses Nat Rev Immunol 8, 34-47
21. Dhodapkar, K. M., Krasovsky, J., Williamson, B., and Dhodapkar, M. V. (2002) Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells J. Exp. Med. 195, 125-133
22. Akiyama, K., Ebihara, S., Yada, A., Matsumura, K., Aiba, S., Nukiwa, T., and Takai, T. (2003) Targeting apoptotic tumor cells to FcγR provides efficient and versatile vaccination against tumors by dendritic cells J. Immunol. 170, 1641-1648
23. Cioca, D. P., Deak, E., Cioca, F., and Paunescu, V. (2005) Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells J. Immunother. 29, 41-52
24. Murillo, O., Dubrot, J., Palazon, A., Arina, A., Azpilikueta, A., Alfaro, C., Solano, S., Ochoa, M. C., Berasain, C., Gabari, I., Perez-Gracia, J. L., Berraondo, P., Hervas-Stubbs, S., and Melero, I. (2009) In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb Eur. J. Immunol. 39, 2424-2436
25. Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., and George, A. J. T. (2010) The safety and side effects of monoclonal antibodies Nat. Rev. Drug Discovery 9, 325-338
26. Getts, D. R., Getts, M. T., McCarthy, D. P., Chastain, E. M., and Miller, S. D. (2010) Have we overestimated the benefit of human(ized) antibodies? mAbs 2, 682-694
27. Harding, F. A., Stickler, M. M., Razo, J., and DuBridge, R. (2010) The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions mAbs 2, 256-265
28. Siberil, S., Dutertre, C.-A., Fridman, W.-H., and Teillaud, J.-L. (2007) FcγR: The key to optimize therapeutic antibodies? Crit. Rev. Oncol. Hematol. 62, 26-33
29. Wu, A. and Senter, P. (2005) Arming antibodies: prospects and challenges for immunoconjugates Nat. Biotechnol. 23, 1137-1146
30. Allen, T. M. (2002) Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2, 750-763
31. Imai, K. and Takaoka, A. (2006) Comparing antibody and small-molecule therapies for cancer Nat. Rev. Cancer 6, 714-727
32. Pashine, A., Valiante, N. M., and Ulmer, J. B. (2005) Targeting the innate immune response with improved vaccine adjuvants Nat. Med. 11, S63-S68
33. Spiegel, D. A. (2010) Grand Challenge Commentary: Synthetic immunology to engineer human immunity Nat. Chem. Biol. 6, 871-872
34. Kodadek, T. (2010) Development of antibody surrogates for the treatment of cancers and autoimmune disease Curr. Opin. Chem. Biol. 14, 721-727
35. Ducry, L. and Stump, B. (2010) Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies Bioconjugate Chem. 21, 5-13
36. Müller, D. and Kontermann, R. E. (2010) Bispecific antibodies for cancer immunotherapy: Current perspectives BioDrugs 24, 89-98
37. Baeuerle, P. A. and Reinhardt, C. (2009) Bispecific T-cell engaging antibodies for cancer therapy Cancer Res. 69, 4941-4944
38. Xiao, J., Chen, R., Pawlicki, M. A., and Tolbert, T. J. (2009) Targeting a homogeneously glycosylated antibody Fc to bind cancer cells using a synthetic receptor ligand J. Am. Chem. Soc. 131, 13616-13618
39. Morelli, L., Poletti, L., and Lay, L. (2011) Carbohydrates and immunology: Synthetic oligosaccharide antigens for vaccine formulation Eur. J. Org. Chem. 2011, 5723-5777
40. Li, Q., So, C. R., Fegan, A., Cody, V., Sarikaya, M., Vallera, D. A., and Wagner, C. R. (2010) Chemically self-assembled antibody nanorings (CSANs): Design and characterization of an anti-CD3 IgM biomimetic J. Am. Chem. Soc. 132, 17247-17257
41. Li, Q., Hapka, D., Chen, H., Vallera, D. A., and Wagner, C. R. (2008) Self-Assembly of Antibodies by Chemical Induction Angew. Chem., Int. Ed. 47, 10179-10182
42. Kitov, P. I., Mulvey, G. L., Griener, T. P., Lipinski, T., Solomon, D., Paszkiewicz, E., Jacobson, J. M., Sadowska, J. M., Suzuki, M., Yamamura, K.-I., Armstrong, G. D., and Bundle, D. R. (2008) In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins Proc. Natl. Acad. Sci. U.S.A. 105, 16837-16842
43. Kitov, P. I., Lipinski, T., Paszkiewicz, E., Solomon, D., Sadowska, J. M., Grant, G. A., Mulvey, G. L., Kitova, E. N., Klassen, J. S., Armstrong, G. D., and Bundle, D. R. (2008) An entropically efficient supramolecular inhibition strategy for shiga toxins Angew. Chem., Int. Ed. 47, 672-676
44. Carlson, J. C. T., Kanter, A., Thuduppathy, G. R., Cody, V., Pineda, P. E., Mcivor, R. S., and Wagner, C. R. (2003) Designing protein dimerizers: the importance of ligand conformational equilibria J. Am. Chem. Soc. 125, 1501-1507
45. Shearer, G. M. (1974) Cell mediated cytotoxicity to trinitrophenyl- modified syngeneic lymphocytes Eur. J. Immunol. 4, 527-533
46. Nelson, D. L., Poplack, D. G., Holiman, B. J., and Henkart, P. A. (1979) ADCC against human erythrocyte target cells: role of the anti-target cell antibodies in determining lymphocyte killer activity Clin. Exp. Immunol. 35, 447-453
47. Six, H. R., Uemura, K., and Kinsky, S. C. (1973) Effect of immunoglobulin class and affinity on the initiation of complement-dependent damage to liposomal model membranes sensitized with dinitrophenylated phospholipids Biochemistry 12, 4003-4011
48. Capon, D. J., Chamow, S. M., Mordenti, J., Marsters, S. A., Gregory, T., Mitsuya, H., Byrn, R. A., Lucas, C., Wurm, F. M., and Groopman, J. E. 1989, Designing CD4 immunoadhesins for AIDS therapy Nature 337, 525-531
49. Traunecker, A., Schneider, J., Kiefer, H., and Karjalainen, K. (1989) Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules Nature 339, 68-70
50. Byrn, R. A., Mordenti, J., Lucas, C., Smith, D., Marsters, S. A., Johnson, J. S., Cossum, P., Chamow, S. M., and Wurm, F. M. 1990, Biological properties of a CD4 immunoadhesin Nature 344, 667-670
51. Shokat, K. M. and Schultz, P. G. (1991) Redirecting the immune response: ligand-mediated immunogenicity J. Am. Chem. Soc. 113, 1861-1862
52. Lussow, A. R., Buelow, R., Fanget, L., Peretto, S., Gao, L., and Pouletty, P. (1996) Redirecting circulating antibodies via ligand-hapten conjugates eliminates target cells in vivo J. Immunother. Emphasis Tumor Immunol. 19, 257-265
53. Bertozzi, C. R. and Bednarski, M. D. (1992) Antibody targeting to bacterial cells using receptor-specific ligands J. Am. Chem. Soc. 114, 2242-2245
54. Bertozzi, C. R. and Bednarski, M. D. (1992) A receptor-mediated immune response using synthetic glycoconjugates J. Am. Chem. Soc. 114, 5543-5546
55. Li, J., Zacharek, S., Chen, X., Wang, J., Zhang, W., Janczuk, A., and Wang, P. G. (1999) Bacteria targeted by human natural antibodies using alpha -gal conjugated receptor-specific glycopolymers Bioorg. Med. Chem. 7, 1549-1558
56. Metallo, S. J., Kane, R. S., Holmlin, R. E., and Whitesides, G. M. (2003) Using bifunctional polymers presenting vancomycin and fluorescein groups to direct anti-fluorescein antibodies to self-assembled monolayers presenting d -alanine- d -alanine groups J. Am. Chem. Soc. 125, 4534-4540
57. Krishnamurthy, V. M., Quinton, L. J., Estroff, L. A., Metallo, S. J., Isaacs, J. M., Mizgerd, J. P., and Whitesides, G. M. (2006) Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunctional polyacrylamide Biomaterials 27, 3663-3674
58. Naicker, K. P., Li, H., Heredia, A., Song, H., and Wang, L.-X. (2004) Design and synthesis of alpha Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting Org. Biomol. Chem. 2, 660-664
59. Perdomo, M. F., Levi, M., Saellberg, M., and Vahlne, A. (2008) Neutralization of HIV-1 by redirection of natural antibodies Proc. Natl. Acad. Sci. U.S.A. 105, 12515-12520
60. Parker, C. G., Domaoal, R. A., Anderson, K. S., and Spiegel, D. A. (2009) An antibody-recruiting small molecule that targets HIV gp120 J. Am. Chem. Soc. 131, 16392-16394
61. Gavrilyuk, J., Uehara, H., Otsubo, N., Hessell, A., Burton, D. R., and Barbas, C. F., 3rd (2010) Potent inhibition of HIV-1 entry with a chemically programmed antibody aided by an efficient organocatalytic synthesis ChemBioChem 11, 2113-2118
62. Lu, Y. and Low, P. S. (2002) Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors Cancer Immunol. Immunother. 51, 153-162
63. Lu, Y., Sega, E., and Low Philip, S. (2005) Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells Int. J. Cancer. 116, 710-719
64. Lu, Y., You, F., Vlahov, I., Westrick, E., Fan, M., Low, P. S., and Leamon, C. P. (2007) Folate-targeted dinitrophenyl hapten immunotherapy: Effect of linker chemistry on antitumor activity and allergic potential Mol. Pharmaceutics 4, 695-706
65. Rader, C., Sinha, S. C., Popkov, M., Lerner, R. A., and Barbas, C. F., III (2003) Chemically programmed monoclonal antibodies for cancer therapy: Adaptor immunotherapy based on a covalent antibody catalyst Proc. Natl. Acad. Sci. U.S.A. 100, 5396-5400
66. Li. (2004) Chemical adaptor immunotherapy: Design, synthesis, and evaluation of novel integrin-targeting devices J. Med. Chem. 47, 5630-5640
67. Popkov, M., Rader, C., Gonzalez, B., Sinha, S. C., and Barbas, C. F., III (2006) Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector Int. J. Cancer 119, 1194-1207
68. Doppalapudi, V., Tryder, N., Li, L., Aja, T., Griffith, D., Liao, F.-F., Roxas, G., Ramprasad, M., Bradshaw, C., and Barbas, C. (2007) Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies Bioorg. Med. Chem. Lett. 17, 501-506
69. Owen, R. M., Carlson, C. B., Xu, J., Mowery, P., Fasella, E., and Kiessling, L. L. (2007) Bifunctional ligands that target cells displaying the alpha vbeta 3 integrin ChemBioChem 8, 68-82
70. Carlson, C. B., Mowery, P., Owen, R. M., Dykhuizen, E. C., and Kiessling, L. L. (2007) Selective tumor cell targeting using low-affinity, multivalent interactions ACS Chem. Biol. 2, 119-127
71. OßReilly, M. K., Collins, B. E., Han, S., Liao, L., Rillahan, C., Kitov, P. I., Bundle, D. R., and Paulson, J. C. (2008) Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells J. Am. Chem. Soc. 130, 7736-7745
72. Cui, L., Kitov, P. I., Completo, G. C., Paulson, J. C., and Bundle, D. R. (2011) Supramolecular complexing of membrane siglec CD22 mediated by a polyvalent heterobifunctional ligand that templates on IgM Bioconjugate Chem. 22, 546-550
73. Popkov, M., Gonzalez, B., Sinha, S. V., and Barbas, C. F., III (2009) Instant immunity through chemically programmable vaccination and covalent self-assembly Proc. Natl. Acad. Sci. U.S.A. 106, 4378-4383
74. Gavrilyuk, J., Wuellner, U., Salahuddin, S., Goswami, R., Sinha, S., and Barbas, C. (2009) An efficient chemical approach to bispecific antibodies and antibodies of high valency Bioorg. Med. Chem. Lett. 19, 3716-3720
75. Murelli, R. P., Zhang, A. X., Michel, J., Jorgensen, W. L., and Spiegel, D. A. (2009) Chemical control over immune recognition: A class of antibody-recruiting small molecules that target prostate cancer J. Am. Chem. Soc. 131, 17090-17092
76. Wuellner, U., Gavrilyuk, J., and Barbas, C. (2010) Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics Angew. Chem., Int. Ed. 49, 5934-5937
77. Doppalapudi, V. R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., Hagen, C., Levin, N. J., Shields, M. J., Parish, M., Murphy, R. E., Del Rosario, J., Oates, B. D., Lai, J.-Y., Matin, M. J., Ainekulu, Z., Bhat, A., Bradshaw, C. W., Woodnutt, G., Lerner, R. A., and Lappe, R. W. (2010) Chemical generation of bispecific antibodies Proc. Natl. Acad. Sci. U.S.A. 107, 22611-22616
78. Dubrovska, A., Kim, C., Elliott, J., Shen, W., Kuo, T.-H., Koo, D.-I., Li, C., Tuntland, T., Chang, J., Groessl, T., Wu, X., Gorney, V., Ramirez Montagut, T., Spiegel, D., Cho, C., and Schultz, P. (2011) A chemically induced vaccine strategy for prostate cancer ACS Chem. Biol. 6, 1223-1231
79. Jakobsche, C. E., McEnaney, P. J., Zhang, A. X., and Spiegel, D. A. (2011) Reprogramming urokinase into an antibody-recruiting anticancer agent ACS Chem. Biol. 7, 316-321
80. Galili, U., Rachmilewitz, E. A., Peleg, A., and Flechner, I. (1984) A unique natural human IgG antibody with anti-alpha -galactosyl specificity J. Exp. Med. 160, 1519-1531
81. Parker, W., Bruno, D., Holzknecht, Z. E., and Platt, J. L. (1994) Characterization and affinity isolation of xenoreactive human natural antibodies J. Immunol. 153, 3791-3803
82. Galili, U., Clark, M. R., Shohet, S. B., Buehler, J., and Macher, B. A. (1987) Evolutionary relationship between the natural anti-Gal antibody and the Galalpha 1 -> 3Gal epitope in primates Proc. Natl. Acad. Sci. U.S.A. 84, 1369-1373
83. Ortega, E., Kostovetzky, M., and Larralde, C. (1984) Natural DNP-binding immunoglobulins and antibody multispecificity Mol. Immunol. 21, 883-888
84. Farah, F. S. (1973) Natural antibodies specific to the 2,4-dinitrophenyl group Immunology 25, 217-226
85. Ju, K.-S. and Parales, R. (2010) Nitroaromatic compounds, from synthesis to biodegradation Microbiol. Mol. Biol. Rev. 74, 250
86. 2,4-Dinitrophenol (CASRN 51-28-5), In http://www.epa.gov/ncea/iris/subst/ 0152.htm, United States Environmental Protection Agency.
87. Harris, M. O. and Cocoran, J. J. (1995) Toxicological Profile for Dinitrophenols, Agency for Toxic Substances and Disease Registry. http://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=729&tid=132.
88. Lauer, K. (1990) Environmental nitrophenols and autoimmunity Mol. Immunol. 27, 697-698
89. Gauba, V., Grünewald, J., Gorney, V., Deaton, L. M., Kang, M., Bursulaya, B., Ou, W., Lerner, R. A., Schmedt, C., Geierstanger, B. H., Schultz, P. G., and Ramirez-Montagut, T. (2011) Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids Proc. Natl. Acad. Sci. U.S.A. 108, 12821-12826
90. Grünewald, J., Hunt, G. S., Dong, L., Niessen, F., Wen, B. G., Tsao, M.-L., Perera, R., Kang, M., Laffitte, B. A., Azarian, S., Ruf, W., Nasoff, M., Lerner, R. A., Schultz, P. G., and Smider, V. V. (2009) Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids Proc. Natl. Acad. Sci. U.S.A. 106, 4337-4342
91. Grünewald, J., Tsao, M.-L., Perera, R., Dong, L., Niessen, F., Wen, B. G., Kubitz, D. M., Smider, V. V., Ruf, W., Nasoff, M., Lerner, R. A., and Schultz, P. G. (2008) Immunochemical termination of self-tolerance Proc. Natl. Acad. Sci. U.S.A. 105, 11276-11280
92. Palm, N. W. and Medzhitov, R. (2009) Immunostimulatory activity of haptenated proteins Proc. Natl. Acad. Sci. U.S.A. 106, 4782-4787
93. Cherukuri, A., Durack, G., and Voss, E. W., Jr. (1997) Evidence for hapten recognition in receptor-mediated intracellular uptake of a hapten-protein conjugate by murine macrophage Mol. Immunol. 34, 21-32
94. Wagner, J., Lerner, R. A., and Barbas, C. F., III (1995) Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes Science 270, 1797-1800
95. Barbas, C. F., Heine, A., Zhong, G., Hoffmann, T., Gramatikova, S., Bjrnestedt, R., List, B., Anderson, J., Stura, E. A., Wilson, I. A., and Lerner, R. A. (1997) Immune versus natural selection: antibody aldolases with enzymic rates but broader scope Science 278, 2085-2092
96. Guo, F., Das, S., Mueller, B., Barbas, C., Lerner, R., and Sinha, S. (2006) Breaking the one antibody-one target axiom Proc. Natl. Acad. Sci. U.S.A. 103, 11009-11014
97. Gavrilyuk, J., Wuellner, U., and Barbas, C. (2009) Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2 Bioorg. Med. Chem. Lett. 19, 1421-1424
98. Tanaka, F. and Barbas, C. F. (2002) Reactive immunization: a unique approach to catalytic antibodies J. Immunol. Methods 269, 67-79
99. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010) Cancer statistics, 2010 CA Cancer J. Clin. 60, 277-300
100. Chabner, B. A. and Roberts, T. G. (2005) Chemotherapy and the war on cancer Nat. Rev. Cancer 5, 65-72
101. Helleday, T., Petermann, E., Lundin, C., Hodgson, B., and Sharma, R. (2008) DNA repair pathways as targets for cancer therapy Nat. Rev. Cancer. 8, 193-204
102. Tennant, D., Duran, R., and Gottlieb, E. (2010) Targeting metabolic transformation for cancer therapy Nat. Rev. Cancer. 10, 267-277
103. Zhang, J., Yang, P., and Gray, N. (2009) Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer. 9, 28-39
104. Drake, C. G. (2010) Prostate cancer as a model for tumour immunotherapy Nat. Rev. Immunol. 10, 580-593
105. Aggarwal, S. (2010) Targeted cancer therapies Nat. Rev. Drug Discovery 9, 427-428
106. Nemeth, J. A., Nakada, M. T., Trikha, M., Lang, Z., Gordon, M. S., Jayson, G. C., Corringham, R., Prabhakar, U., Davis, H. M., and Beckman, R. A. (2007) Alpha-v integrins as therapeutic targets in oncology Cancer Invest. 25, 632-646
107. Felding-Habermann, B. (2003) Integrin adhesion receptors in tumor metastasis Clin. Exp. Metastasis 20, 203-213
108. Chattopadhyay, N. and Chatterjee, A. (2001) Studies on the expression of alpha(v)beta3 integrin receptors in non-malignant and malignant human cervical tumor tissues J. Exp. Clin. Cancer Res. 20, 269-275
109. Wong, N. C., Mueller, B. M., Barbas, C. F., Ruminski, P., Quaranta, V., Lin, E. C., and Smith, J. W. (1998) Alphav integrins mediate adhesion and migration of breast carcinoma cell lines Clin. Exp. Metastasis 16, 50-61
110. Nelson, J., Bagnato, A., Battistini, B., and Nisen, P. (2003) The endothelin axis: emerging role in cancer Nat. Rev. Cancer 3, 110-116
111. Remuzzi, G., Perico, N., and Benigni, A. (2002) New therapeutics that antagonize endothelin: promises and frustrations Nat. Rev. Drug Discovery 1, 986-1001
112. Attin, T., Camidge, R., Newby, D. E., and Webb, D. J. (2005) Endothelin antagonism in pulmonary hypertension, heart failure, and beyond Heart 91, 825-831
113. Li, L. N., Leedom, T. A., Do, J., Huang, H. H., Lai, J. Y., Johnson, K., Osothprarop, T. F., Rizzo, J. D., Doppalapudi, V. R., Bradshaw, C. W., Lappe, R. W., Woodnutt, G., Levin, N. J., and Pirie-Shepherd, S. R. (2011) Antitumor efficacy of a thrombospondin 1 mimetic CovX-Body Transl. Oncol. 4, 239-247
114. Huang, H., Lai, J.-Y., Do, J., Liu, D., Li, L., Del Rosario, J., Doppalapudi, V. R., Pirie-Shepherd, S., Levin, N., Bradshaw, C., Woodnutt, G., Lappe, R., and Bhat, A. (2011) Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth Clin. Cancer Res. 17, 1001-1011
115. Ellington, A. D. and Szostak, J. W. (1990) In vitro selection of RNA molecules that bind specific ligands Nature 346, 818-822
116. Tuerk, C. and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249, 505-510
117. Crocker, P. R., Paulson, J. C., and Varki, A. (2007) Siglecs and their roles in the immune system Nat. Rev. Immunol. 7, 255-266
118. Lu, Y., Sega, E., Leamon, C., and Low, P. (2004) Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential Adv. Drug Delivery Rev. 56, 1161-1176
119. Chames, P., Van Regenmortel, M., Weiss, E., and Baty, D. (2009) Therapeutic antibodies: successes, limitations and hopes for the future Br. J. Pharmacol. 157, 220-233
120. Ellenhorn, J. D., Schreiber, H., and Bluestone, J. A. (1990) Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice J. Immunol. 144, 2840-2846
121. Runyon, K., Lee, K., Zuberek, K., Collins, M., Leonard, J. P., and Dunussi Joannopoulos, K. (2001) The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses Blood 97, 2420-2426
122. Ruf, P. and Lindhofer, H. (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody Blood 98, 2526-2534
123. Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y., Ruf, P., and Slavin, S. (2008) Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody Exp. Hematol. 36, 997-1003
124. Zhang, A., Murelli, R., Barinka, C., Michel, J., Cocleaza, A., Jorgensen, W., Lubkowski, J., and Spiegel, D. (2010) A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules J. Am. Chem. Soc. 132, 12711-12716
125. Holmes, E. H., Greene, T. G., Tino, W. T., Boynton, A. L., Aldape, H. C., Misrock, S. L., and Murphy, G. P. (1996) Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients Prostate Suppl. 7, 25-29
126. Wernicke, A. G., Edgar, M., Lavi, E., Liu, H., Salerno, P., Bander, N., and Gutin, P. (2011) Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme Archi. Pathol. Lab. Med. 135, 1486-1489
127. Samplaski, M., Heston, W., Elson, P., Magi Galluzzi, C., and Hansel, D. (2011) Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature Mod. Pathol. 24, 1521-1529
128. Haffner, M., Kronberger, I., Ross, J., Sheehan, C., Zitt, M., Mhlmann, G., Ofner, D., Zelger, B., Ensinger, C., Yang, X., Geley, S., Margreiter, R., and Bander, N. (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers Hum. Pathol. 40, 1754-1761
129. Blasi, F. and Carmeliet, P. (2002) uPAR: a versatile signalling orchestrator Nat. Rev. Mol. Cell Biol. 3, 932-943
130. Romer, J., Nielsen, B., and Ploug, M. (2004) The urokinase receptor as a potential target in cancer therapy Curr. Pharm. Des. 10, 2359-2376
131. Andreasen, P. A., Kjller, L., Christensen, L., and Duffy, M. J. (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review Int. J. Cancer 72, 1-22
132. Duffy, M. J., Ogrady, P., Devaney, D., OßSiorain, L., Fennelly, J. J., and Lijnen, H. J. (1988) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report Cancer 62, 531-533
133. Sier, C. F., Stephens, R., Bizik, J., Mariani, A., Bassan, M., Pedersen, N., Frigerio, L., Ferrari, A., Dan, K., Brnner, N., and Blasi, F. (1998) The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients Cancer Res. 58, 1843-1849
134. Harbeck, N., Kates, R., Gauger, K., Willems, A., Kiechle, M., Magdolen, V., and Schmitt, M. (2004) Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer Thrombosis Haemostasis 91, 450-456
135. Konecny, G., Untch, M., Pihan, A., Kimmig, R., Gropp, M., Stieber, P., Hepp, H., Slamon, D., and Pegram, M. (2001) Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer Clin. Cancer Res. 7, 1743-1749
136. Mathers, C., Boerma, T., and Ma Fat, D. (2008) The Global Burden of Disease, 2004 update, ed., p 146, World Health Organization, Geneva, Switzerland.
137. Rappuoli, R., Mandl, C. W., Black, S., and De Gregorio, E. (2011) Vaccines for the twenty-first century society Nat. Rev. Immunol. 11, 865-872
138. Hilleman, M. R. (2000) Vaccines in historic evolution and perspective: a narrative of vaccine discoveries Vaccine 18, 1436-1447
139. Ulmer, J. B., Valley, U., and Rappuoli, R. (2006) Vaccine manufacturing: challenges and solutions Nat. Biotechnol. 24, 1377-1383
140. Plotkin, S. A. (2009) Vaccines: the fourth century Clin. Vaccine Immunol. 16, 1709-1719
141. Guy, B. (2007) The perfect mix: recent progress in adjuvant research Nat. Rev. Microbiol. 5, 505-517
142. Sheridan, C. (2005) The business of making vaccines Nat. Biotechnol. 23, 1359-1366
143. Palumbi, S. R. (2001) Humans as the worldβs greatest evolutionary force Science 293, 1786-1790
144. Razonable, R. R. (2011) Antiviral drugs for viruses other than human immunodeficiency virus Mayo Clin. Proc. 86, 1009-1026
145. Saylor, C., Dadachova, E., and Casadevall, A. (2009) Monoclonal antibody-based therapies for microbial diseases Vaccine 27 (Suppl 6) G38-46
146. Nagy, E., Giefing, C., and von Gabain, A. (2008) Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases Expert Rev. Anti-Infect. Ther.. 6, 21-30
147. Bebbington, C. and Yarranton, G. (2008) Antibodies for the treatment of bacterial infections: current experience and future prospects Curr. Opin. Biotechnol. 19, 613-619
148. ter Meulen, J. (2007) Monoclonal antibodies for prophylaxis and therapy of infectious diseases Expert Opin. Emerging Drugs 12, 525-540
149. Xiao, X. and Dimitrov, D. S. (2007) Monoclonal antibodies against viruses and bacteria: a survey of patents Recent Pat. Antiinfect. Drug Discovery 2, 171-177
150. Jan, t. M. (2011) Monoclonal antibodies in infectious diseases: Clinical pipeline in 2011 Infect. Dis. Clin. North Am. 25, 789-802
151. Sekirov, I., Tam, N. M., Jogova, M., Robertson, M. L., Li, Y., Lupp, C., and Finlay, B. B. (2008) Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection Infect. Immun. 76, 4726-4736
152. Willing, B. P., Russell, S. L., and Finlay, B. B. (2011) Shifting the balance: antibiotic effects on host-microbiota mutualism Nat. Rev. Microbiol. 9, 233-243
153. Walsh, C. (2000) Molecular mechanisms that confer antibacterial drug resistance Nature 406, 775-781
154. Nikaido, H. (2009) Multidrug resistance in bacteria Annu. Rev. Biochem. 78, 119-146
155. Cooper, M. A. and Shlaes, D. (2011) Fix the antibiotics pipeline Nature 472, 32
156. Huang, D. B., Wu, J. J., and Tyring, S. K. (2004) A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines J. Infect. 49, 179-209
157. Berzofsky, J. A., Ahlers, J. D., Janik, J., Morris, J., Oh, S., Terabe, M., and Belyakov, I. M. (2004) Progress on new vaccine strategies against chronic viral infections J. Clin. Invest. 114, 450-462
158. Carreiras, F., Denoux, Y., Staedel, C., Lehmann, M., Sichel, F., and Gauduchon, P. (1996) Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma Gynecol. Oncol. 62, 260-267
159. Margeridon-Thermet, S. and Shafer, R. W. (2010) Comparison of the mechanisms of drug resistance among HIV, Hepatitis B, and Hepatitis C Viruses 2, 2696-2739
160. Griffiths, P. D. (2009) A perspective on antiviral resistance J. Clin. Virol. 46, 3-8
161. De Clercq, E. (2002) Strategies in the design of antiviral drugs Nat. Rev. Drug Discovery 1, 13-25
162. Dessain, S. K., Adekar, S. P., and Berry, J. D. (2008) Exploring the native human antibody repertoire to create antiviral therapeutics Curr. Top. Microbiol. Immunol. 317, 155-183
163. Wang, T., Zhang, Z., Wallace, O. B., Deshpande, M., Fang, H., Yang, Z., Zadjura, L. M., Tweedie, D. L., Huang, S., Zhao, F., Ranadive, S., Robinson, B. S., Gong, Y. F., Ricarrdi, K., Spicer, T. P., Deminie, C., Rose, R., Wang, H. G., Blair, W. S., Shi, P. Y., Lin, P. F., Colonno, R. J., and Meanwell, N. A. (2003) Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl) oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions J. Med. Chem. 46, 4236-4239
164. Reddy, A. S., Pati, S. P., Kumar, P. P., Pradeep, H. N., and Sastry, G. N. (2007) Virtual screening in drug discovery-A computational perspective Curr. Protein Pept. Sci. 8, 329-351
165. Lange, T. and Lindell, S. (2005) Recent advances in microwave-assisted combinatorial synthesis and library generation Comb. Chem. High Throughput Screening 8, 595-606
166. Osmond, R. I. W., Das, S., and Crouch, M. F. (2010) Development of cell-based assays for cytokine receptor signaling, using an AlphaScreen SureFire assay format Anal. Biochem. 403, 94-101
167. Oyelaran, O., McShane, L. M., Dodd, L., and Gildersleeve, J. C. (2009) Profiling human serum antibodies with a carbohydrate antigen microarray J. Proteome Res. 8, 4301-4310
168. Huflejt, M. E., Vuskovic, M., Vasiliu, D., Xu, H., Obukhova, P., Shilova, N., Tuzikov, A., Galanina, O., Arun, B., Lu, K., and Bovin, N. (2009) Anti-carbohydrate antibodies of normal sera: Findings, surprises and challenges Mol. Immunol. 46, 3037-3049
169. Chen, W., Gu, L., Zhang, W., Motari, E., Cai, L., Styslinger, T. J., and Wang, P. G. (2011) L-Rhamnose antigen: a promising alternative to alpha -Gal for cancer immunotherapies ACS Chem. Biol. 6, 185-191
170. Reddy, M. M., Wilson, R., Wilson, J., Connell, S., Gocke, A., Hynan, L., German, D., and Kodadek, T. (2011) Identification of candidate IgG biomarkers for AlzheimerβS Disease via combinatorial library screening Cell 144, 132-142
171. Sergeeva, A., Kolonin, M. G., Molldrem, J. J., Pasqualini, R., and Arap, W. (2006) Display technologies: Application for the discovery of drug and gene delivery agents Adv. Drug Delivery Rev. 58, 1622-1654
172. Udugamasooriya, D. G., Dineen, S. P., Brekken, R. A., and Kodadek, T. (2008) A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity J. Am. Chem. Soc. 130, 5744-5752
173. Buller, F., Steiner, M., Frey, K., Mircsof, D., Scheuermann, J., Kalisch, M., Buhlmann, P., Supuran, C. T., and Neri, D. (2011) Selection of carbonic anhydrase IX inhibitors from one million DNA-Encoded compounds ACS Chem. Biol. 6, 336-344
174. Meireles, L. M. C. and Mustata, G. (2011) Discovery of modulators of protein-protein interactions: current approaches and limitations Curr. Top. Med. Chem. 11, 248-257
175. Mammen, M., Choi, S. K., and Whitesides, G. M. (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors Angew. Chem., Int. Ed. 37, 2755-2794
176. Lim, R. K. V. and Lin, Q. (2010) Bioorthogonal chemistry: recent progress and future directions Chem. Commun. 46, 1589-1600
177. Sletten, E. M. and Bertozzi, C. R. (2009) Bioorthogonal chemistry: